0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Malignant Mesothelioma Market Insights, Forecast to 2029
Published Date: June 2023
|
Report Code: QYRE-Auto-2N14158
Home | Market Reports | Health| Health Conditions| Cancer
Global Malignant Mesothelioma Market Research Report 2023
BUY CHAPTERS

Global Malignant Mesothelioma Market Insights, Forecast to 2029

Code: QYRE-Auto-2N14158
Report
June 2023
Pages:128
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Malignant Mesothelioma Market Size

The global Malignant Mesothelioma market is projected to grow from US$ 475.3 million in 2023 to US$ 674.2 million by 2029, at a Compound Annual Growth Rate (CAGR) of 6.0% during the forecast period.

Malignant Mesothelioma Market

Malignant Mesothelioma Market

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Market Analysis and Insights: Global Malignant Mesothelioma Market
Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.
Report Includes
This report presents an overview of global market for Malignant Mesothelioma market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Malignant Mesothelioma, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Malignant Mesothelioma, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Malignant Mesothelioma revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Malignant Mesothelioma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Malignant Mesothelioma revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly and Teva Pharmaceuticals, etc.

Scope of Malignant Mesothelioma Market Report

Report Metric Details
Report Name Malignant Mesothelioma Market
Accounted market size in 2023 US$ 475.3 million
Forecasted market size in 2029 US$ 674.2 million
Base Year 2023
Forecasted years 2023 - 2029
Segment by Type
  • Oral
  • Parenteral
Segment by Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Malignant Mesothelioma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Malignant Mesothelioma companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America by type, by application and by country, revenue for each segment.
  • Chapter 7: Europe by type, by application and by country, revenue for each segment.
  • Chapter 8: China by type and by application revenue for each segment.
  • Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Malignant Mesothelioma revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Parenteral
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Oncology Centers
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Market Perspective (2018-2029)
2.2 Global Malignant Mesothelioma Growth Trends by Region
2.2.1 Malignant Mesothelioma Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Malignant Mesothelioma Historic Market Size by Region (2018-2023)
2.2.3 Malignant Mesothelioma Forecasted Market Size by Region (2024-2029)
2.3 Malignant Mesothelioma Market Dynamics
2.3.1 Malignant Mesothelioma Industry Trends
2.3.2 Malignant Mesothelioma Market Drivers
2.3.3 Malignant Mesothelioma Market Challenges
2.3.4 Malignant Mesothelioma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Malignant Mesothelioma by Players
3.1.1 Global Malignant Mesothelioma Revenue by Players (2018-2023)
3.1.2 Global Malignant Mesothelioma Revenue Market Share by Players (2018-2023)
3.2 Global Malignant Mesothelioma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Malignant Mesothelioma, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Malignant Mesothelioma Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Revenue in 2022
3.5 Global Key Players of Malignant Mesothelioma Head office and Area Served
3.6 Global Key Players of Malignant Mesothelioma, Product and Application
3.7 Global Key Players of Malignant Mesothelioma, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Mesothelioma Breakdown Data by Type
4.1 Global Malignant Mesothelioma Historic Market Size by Type (2018-2023)
4.2 Global Malignant Mesothelioma Forecasted Market Size by Type (2024-2029)
5 Malignant Mesothelioma Breakdown Data by Application
5.1 Global Malignant Mesothelioma Historic Market Size by Application (2018-2023)
5.2 Global Malignant Mesothelioma Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Malignant Mesothelioma Market Size (2018-2029)
6.2 North America Malignant Mesothelioma Market Size by Type
6.2.1 North America Malignant Mesothelioma Market Size by Type (2018-2023)
6.2.2 North America Malignant Mesothelioma Market Size by Type (2024-2029)
6.2.3 North America Malignant Mesothelioma Market Share by Type (2018-2029)
6.3 North America Malignant Mesothelioma Market Size by Application
6.3.1 North America Malignant Mesothelioma Market Size by Application (2018-2023)
6.3.2 North America Malignant Mesothelioma Market Size by Application (2024-2029)
6.3.3 North America Malignant Mesothelioma Market Share by Application (2018-2029)
6.4 North America Malignant Mesothelioma Market Size by Country
6.4.1 North America Malignant Mesothelioma Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Malignant Mesothelioma Market Size by Country (2018-2023)
6.4.3 North America Malignant Mesothelioma Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Market Size (2018-2029)
7.2 Europe Malignant Mesothelioma Market Size by Type
7.2.1 Europe Malignant Mesothelioma Market Size by Type (2018-2023)
7.2.2 Europe Malignant Mesothelioma Market Size by Type (2024-2029)
7.2.3 Europe Malignant Mesothelioma Market Share by Type (2018-2029)
7.3 Europe Malignant Mesothelioma Market Size by Application
7.3.1 Europe Malignant Mesothelioma Market Size by Application (2018-2023)
7.3.2 Europe Malignant Mesothelioma Market Size by Application (2024-2029)
7.3.3 Europe Malignant Mesothelioma Market Share by Application (2018-2029)
7.4 Europe Malignant Mesothelioma Market Size by Country
7.4.1 Europe Malignant Mesothelioma Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Malignant Mesothelioma Market Size by Country (2018-2023)
7.4.3 Europe Malignant Mesothelioma Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Malignant Mesothelioma Market Size (2018-2029)
8.2 China Malignant Mesothelioma Market Size by Type
8.2.1 China Malignant Mesothelioma Market Size by Type (2018-2023)
8.2.2 China Malignant Mesothelioma Market Size by Type (2024-2029)
8.2.3 China Malignant Mesothelioma Market Share by Type (2018-2029)
8.3 China Malignant Mesothelioma Market Size by Application
8.3.1 China Malignant Mesothelioma Market Size by Application (2018-2023)
8.3.2 China Malignant Mesothelioma Market Size by Application (2024-2029)
8.3.3 China Malignant Mesothelioma Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Malignant Mesothelioma Market Size (2018-2029)
9.2 Asia Malignant Mesothelioma Market Size by Type
9.2.1 Asia Malignant Mesothelioma Market Size by Type (2018-2023)
9.2.2 Asia Malignant Mesothelioma Market Size by Type (2024-2029)
9.2.3 Asia Malignant Mesothelioma Market Share by Type (2018-2029)
9.3 Asia Malignant Mesothelioma Market Size by Application
9.3.1 Asia Malignant Mesothelioma Market Size by Application (2018-2023)
9.3.2 Asia Malignant Mesothelioma Market Size by Application (2024-2029)
9.3.3 Asia Malignant Mesothelioma Market Share by Application (2018-2029)
9.4 Asia Malignant Mesothelioma Market Size by Region
9.4.1 Asia Malignant Mesothelioma Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Malignant Mesothelioma Market Size by Region (2018-2023)
9.4.3 Asia Malignant Mesothelioma Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Type
10.2.1 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Malignant Mesothelioma Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Application
10.3.1 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Malignant Mesothelioma Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Country
10.4.1 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Malignant Mesothelioma Introduction
11.1.4 AstraZeneca Revenue in Malignant Mesothelioma Business (2018-2023)
11.1.5 AstraZeneca Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Malignant Mesothelioma Introduction
11.2.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2018-2023)
11.2.5 Bristol-Myers Squibb Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Malignant Mesothelioma Introduction
11.3.4 Roche Revenue in Malignant Mesothelioma Business (2018-2023)
11.3.5 Roche Recent Developments
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Malignant Mesothelioma Introduction
11.4.4 Merck Revenue in Malignant Mesothelioma Business (2018-2023)
11.4.5 Merck Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Malignant Mesothelioma Introduction
11.5.4 Novartis Revenue in Malignant Mesothelioma Business (2018-2023)
11.5.5 Novartis Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Malignant Mesothelioma Introduction
11.6.4 Pfizer Revenue in Malignant Mesothelioma Business (2018-2023)
11.6.5 Pfizer Recent Developments
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Malignant Mesothelioma Introduction
11.7.4 Sanofi Revenue in Malignant Mesothelioma Business (2018-2023)
11.7.5 Sanofi Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Malignant Mesothelioma Introduction
11.8.4 Eli Lilly Revenue in Malignant Mesothelioma Business (2018-2023)
11.8.5 Eli Lilly Recent Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Details
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals Malignant Mesothelioma Introduction
11.9.4 Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023)
11.9.5 Teva Pharmaceuticals Recent Developments
11.10 Boehringer Ingelheim GmbH
11.10.1 Boehringer Ingelheim GmbH Company Details
11.10.2 Boehringer Ingelheim GmbH Business Overview
11.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Introduction
11.10.4 Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2018-2023)
11.10.5 Boehringer Ingelheim GmbH Recent Developments
11.11 Mylan
11.11.1 Mylan Company Details
11.11.2 Mylan Business Overview
11.11.3 Mylan Malignant Mesothelioma Introduction
11.11.4 Mylan Revenue in Malignant Mesothelioma Business (2018-2023)
11.11.5 Mylan Recent Developments
11.12 Fresenius Kabi
11.12.1 Fresenius Kabi Company Details
11.12.2 Fresenius Kabi Business Overview
11.12.3 Fresenius Kabi Malignant Mesothelioma Introduction
11.12.4 Fresenius Kabi Revenue in Malignant Mesothelioma Business (2018-2023)
11.12.5 Fresenius Kabi Recent Developments
11.13 Sun Pharmaceuticals
11.13.1 Sun Pharmaceuticals Company Details
11.13.2 Sun Pharmaceuticals Business Overview
11.13.3 Sun Pharmaceuticals Malignant Mesothelioma Introduction
11.13.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023)
11.13.5 Sun Pharmaceuticals Recent Developments
11.14 Corden Pharma
11.14.1 Corden Pharma Company Details
11.14.2 Corden Pharma Business Overview
11.14.3 Corden Pharma Malignant Mesothelioma Introduction
11.14.4 Corden Pharma Revenue in Malignant Mesothelioma Business (2018-2023)
11.14.5 Corden Pharma Recent Developments
11.15 Concordia International
11.15.1 Concordia International Company Details
11.15.2 Concordia International Business Overview
11.15.3 Concordia International Malignant Mesothelioma Introduction
11.15.4 Concordia International Revenue in Malignant Mesothelioma Business (2018-2023)
11.15.5 Concordia International Recent Developments
11.16 Kyowa Hakko Kirin
11.16.1 Kyowa Hakko Kirin Company Details
11.16.2 Kyowa Hakko Kirin Business Overview
11.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Introduction
11.16.4 Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2018-2023)
11.16.5 Kyowa Hakko Kirin Recent Developments
11.17 Polaris Pharmaceuticals
11.17.1 Polaris Pharmaceuticals Company Details
11.17.2 Polaris Pharmaceuticals Business Overview
11.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Introduction
11.17.4 Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023)
11.17.5 Polaris Pharmaceuticals Recent Developments
11.18 MolMed
11.18.1 MolMed Company Details
11.18.2 MolMed Business Overview
11.18.3 MolMed Malignant Mesothelioma Introduction
11.18.4 MolMed Revenue in Malignant Mesothelioma Business (2018-2023)
11.18.5 MolMed Recent Developments
11.19 Ono Pharmaceutical
11.19.1 Ono Pharmaceutical Company Details
11.19.2 Ono Pharmaceutical Business Overview
11.19.3 Ono Pharmaceutical Malignant Mesothelioma Introduction
11.19.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023)
11.19.5 Ono Pharmaceutical Recent Developments
11.20 Nichi-Iko Pharmaceutical
11.20.1 Nichi-Iko Pharmaceutical Company Details
11.20.2 Nichi-Iko Pharmaceutical Business Overview
11.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Introduction
11.20.4 Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023)
11.20.5 Nichi-Iko Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Malignant Mesothelioma Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
    Table 2. Key Players of Oral
    Table 3. Key Players of Parenteral
    Table 4. Global Malignant Mesothelioma Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
    Table 5. Global Malignant Mesothelioma Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 6. Global Malignant Mesothelioma Market Size by Region (2018-2023) & (US$ Million)
    Table 7. Global Malignant Mesothelioma Market Share by Region (2018-2023)
    Table 8. Global Malignant Mesothelioma Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 9. Global Malignant Mesothelioma Market Share by Region (2024-2029)
    Table 10. Malignant Mesothelioma Market Trends
    Table 11. Malignant Mesothelioma Market Drivers
    Table 12. Malignant Mesothelioma Market Challenges
    Table 13. Malignant Mesothelioma Market Restraints
    Table 14. Global Malignant Mesothelioma Revenue by Players (2018-2023) & (US$ Million)
    Table 15. Global Malignant Mesothelioma Revenue Share by Players (2018-2023)
    Table 16. Global Top Malignant Mesothelioma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma as of 2022)
    Table 17. Global Malignant Mesothelioma Industry Ranking 2021 VS 2022 VS 2023
    Table 18. Global 5 Largest Players Market Share by Malignant Mesothelioma Revenue (CR5 and HHI) & (2018-2023)
    Table 19. Global Key Players of Malignant Mesothelioma, Headquarters and Area Served
    Table 20. Global Key Players of Malignant Mesothelioma, Product and Application
    Table 21. Global Key Players of Malignant Mesothelioma, Product and Application
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Malignant Mesothelioma Market Size by Type (2018-2023) & (US$ Million)
    Table 24. Global Malignant Mesothelioma Revenue Market Share by Type (2018-2023)
    Table 25. Global Malignant Mesothelioma Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 26. Global Malignant Mesothelioma Revenue Market Share by Type (2024-2029)
    Table 27. Global Malignant Mesothelioma Market Size by Application (2018-2023) & (US$ Million)
    Table 28. Global Malignant Mesothelioma Revenue Share by Application (2018-2023)
    Table 29. Global Malignant Mesothelioma Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 30. Global Malignant Mesothelioma Revenue Share by Application (2024-2029)
    Table 31. North America Malignant Mesothelioma Market Size by Type (2018-2023) & (US$ Million)
    Table 32. North America Malignant Mesothelioma Market Size by Type (2024-2029) & (US$ Million)
    Table 33. North America Malignant Mesothelioma Market Size by Application (2018-2023) & (US$ Million)
    Table 34. North America Malignant Mesothelioma Market Size by Application (2024-2029) & (US$ Million)
    Table 35. North America Malignant Mesothelioma Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 36. North America Malignant Mesothelioma Market Size by Country (2018-2023) & (US$ Million)
    Table 37. North America Malignant Mesothelioma Market Size by Country (2024-2029) & (US$ Million)
    Table 38. Europe Malignant Mesothelioma Market Size by Type (2018-2023) & (US$ Million)
    Table 39. Europe Malignant Mesothelioma Market Size by Type (2024-2029) & (US$ Million)
    Table 40. Europe Malignant Mesothelioma Market Size by Application (2018-2023) & (US$ Million)
    Table 41. Europe Malignant Mesothelioma Market Size by Application (2024-2029) & (US$ Million)
    Table 42. Europe Malignant Mesothelioma Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 43. Europe Malignant Mesothelioma Market Size by Country (2018-2023) & (US$ Million)
    Table 44. Europe Malignant Mesothelioma Market Size by Country (2024-2029) & (US$ Million)
    Table 45. China Malignant Mesothelioma Market Size by Type (2018-2023) & (US$ Million)
    Table 46. China Malignant Mesothelioma Market Size by Type (2024-2029) & (US$ Million)
    Table 47. China Malignant Mesothelioma Market Size by Application (2018-2023) & (US$ Million)
    Table 48. China Malignant Mesothelioma Market Size by Application (2024-2029) & (US$ Million)
    Table 49. Asia Malignant Mesothelioma Market Size by Type (2018-2023) & (US$ Million)
    Table 50. Asia Malignant Mesothelioma Market Size by Type (2024-2029) & (US$ Million)
    Table 51. Asia Malignant Mesothelioma Market Size by Application (2018-2023) & (US$ Million)
    Table 52. Asia Malignant Mesothelioma Market Size by Application (2024-2029) & (US$ Million)
    Table 53. Asia Malignant Mesothelioma Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 54. Asia Malignant Mesothelioma Market Size by Region (2018-2023) & (US$ Million)
    Table 55. Asia Malignant Mesothelioma Market Size by Region (2024-2029) & (US$ Million)
    Table 56. Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Type (2018-2023) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Type (2024-2029) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Application (2018-2023) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Application (2024-2029) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Malignant Mesothelioma Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 61. Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Country (2018-2023) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Malignant Mesothelioma Market Size by Country (2024-2029) & (US$ Million)
    Table 63. AstraZeneca Company Details
    Table 64. AstraZeneca Business Overview
    Table 65. AstraZeneca Malignant Mesothelioma Product
    Table 66. AstraZeneca Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 67. AstraZeneca Recent Developments
    Table 68. Bristol-Myers Squibb Company Details
    Table 69. Bristol-Myers Squibb Business Overview
    Table 70. Bristol-Myers Squibb Malignant Mesothelioma Product
    Table 71. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 72. Bristol-Myers Squibb Recent Developments
    Table 73. Roche Company Details
    Table 74. Roche Business Overview
    Table 75. Roche Malignant Mesothelioma Product
    Table 76. Roche Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 77. Roche Recent Developments
    Table 78. Merck Company Details
    Table 79. Merck Business Overview
    Table 80. Merck Malignant Mesothelioma Product
    Table 81. Merck Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 82. Merck Recent Developments
    Table 83. Novartis Company Details
    Table 84. Novartis Business Overview
    Table 85. Novartis Malignant Mesothelioma Product
    Table 86. Novartis Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 87. Novartis Recent Developments
    Table 88. Pfizer Company Details
    Table 89. Pfizer Business Overview
    Table 90. Pfizer Malignant Mesothelioma Product
    Table 91. Pfizer Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 92. Pfizer Recent Developments
    Table 93. Sanofi Company Details
    Table 94. Sanofi Business Overview
    Table 95. Sanofi Malignant Mesothelioma Product
    Table 96. Sanofi Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 97. Sanofi Recent Developments
    Table 98. Eli Lilly Company Details
    Table 99. Eli Lilly Business Overview
    Table 100. Eli Lilly Malignant Mesothelioma Product
    Table 101. Eli Lilly Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 102. Eli Lilly Recent Developments
    Table 103. Teva Pharmaceuticals Company Details
    Table 104. Teva Pharmaceuticals Business Overview
    Table 105. Teva Pharmaceuticals Malignant Mesothelioma Product
    Table 106. Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 107. Teva Pharmaceuticals Recent Developments
    Table 108. Boehringer Ingelheim GmbH Company Details
    Table 109. Boehringer Ingelheim GmbH Business Overview
    Table 110. Boehringer Ingelheim GmbH Malignant Mesothelioma Product
    Table 111. Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 112. Boehringer Ingelheim GmbH Recent Developments
    Table 113. Mylan Company Details
    Table 114. Mylan Business Overview
    Table 115. Mylan Malignant Mesothelioma Product
    Table 116. Mylan Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 117. Mylan Recent Developments
    Table 118. Fresenius Kabi Company Details
    Table 119. Fresenius Kabi Business Overview
    Table 120. Fresenius Kabi Malignant Mesothelioma Product
    Table 121. Fresenius Kabi Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 122. Fresenius Kabi Recent Developments
    Table 123. Sun Pharmaceuticals Company Details
    Table 124. Sun Pharmaceuticals Business Overview
    Table 125. Sun Pharmaceuticals Malignant Mesothelioma Product
    Table 126. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 127. Sun Pharmaceuticals Recent Developments
    Table 128. Corden Pharma Company Details
    Table 129. Corden Pharma Business Overview
    Table 130. Corden Pharma Malignant Mesothelioma Product
    Table 131. Corden Pharma Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 132. Corden Pharma Recent Developments
    Table 133. Concordia International Company Details
    Table 134. Concordia International Business Overview
    Table 135. Concordia International Malignant Mesothelioma Product
    Table 136. Concordia International Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 137. Concordia International Recent Developments
    Table 138. Kyowa Hakko Kirin Company Details
    Table 139. Kyowa Hakko Kirin Business Overview
    Table 140. Kyowa Hakko Kirin Malignant Mesothelioma Product
    Table 141. Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 142. Kyowa Hakko Kirin Recent Developments
    Table 143. Polaris Pharmaceuticals Company Details
    Table 144. Polaris Pharmaceuticals Business Overview
    Table 145. Polaris Pharmaceuticals Malignant Mesothelioma Product
    Table 146. Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 147. Polaris Pharmaceuticals Recent Developments
    Table 148. MolMed Company Details
    Table 149. MolMed Business Overview
    Table 150. MolMed Malignant Mesothelioma Product
    Table 151. MolMed Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 152. MolMed Recent Developments
    Table 153. Ono Pharmaceutical Company Details
    Table 154. Ono Pharmaceutical Business Overview
    Table 155. Ono Pharmaceutical Malignant Mesothelioma Product
    Table 156. Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 157. Ono Pharmaceutical Recent Developments
    Table 158. Nichi-Iko Pharmaceutical Company Details
    Table 159. Nichi-Iko Pharmaceutical Business Overview
    Table 160. Nichi-Iko Pharmaceutical Malignant Mesothelioma Product
    Table 161. Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)
    Table 162. Nichi-Iko Pharmaceutical Recent Developments
    Table 163. Research Programs/Design for This Report
    Table 164. Key Data Information from Secondary Sources
    Table 165. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Malignant Mesothelioma Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 2. Global Malignant Mesothelioma Market Share by Type: 2022 VS 2029
    Figure 3. Oral Features
    Figure 4. Parenteral Features
    Figure 5. Global Malignant Mesothelioma Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 6. Global Malignant Mesothelioma Market Share by Application: 2022 VS 2029
    Figure 7. Hospital Pharmacies Case Studies
    Figure 8. Retail Pharmacies Case Studies
    Figure 9. Oncology Centers Case Studies
    Figure 10. Others Case Studies
    Figure 11. Malignant Mesothelioma Report Years Considered
    Figure 12. Global Malignant Mesothelioma Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 13. Global Malignant Mesothelioma Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 14. Global Malignant Mesothelioma Market Share by Region: 2022 VS 2029
    Figure 15. Global Malignant Mesothelioma Market Share by Players in 2022
    Figure 16. Global Top Malignant Mesothelioma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma as of 2022)
    Figure 17. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Revenue in 2022
    Figure 18. North America Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 19. North America Malignant Mesothelioma Market Share by Type (2018-2029)
    Figure 20. North America Malignant Mesothelioma Market Share by Application (2018-2029)
    Figure 21. North America Malignant Mesothelioma Market Share by Country (2018-2029)
    Figure 22. United States Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Canada Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Europe Malignant Mesothelioma Market Size YoY (2018-2029) & (US$ Million)
    Figure 25. Europe Malignant Mesothelioma Market Share by Type (2018-2029)
    Figure 26. Europe Malignant Mesothelioma Market Share by Application (2018-2029)
    Figure 27. Europe Malignant Mesothelioma Market Share by Country (2018-2029)
    Figure 28. Germany Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. France Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. U.K. Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Italy Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Russia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Nordic Countries Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. China Malignant Mesothelioma Market Size YoY (2018-2029) & (US$ Million)
    Figure 35. China Malignant Mesothelioma Market Share by Type (2018-2029)
    Figure 36. China Malignant Mesothelioma Market Share by Application (2018-2029)
    Figure 37. Asia Malignant Mesothelioma Market Size YoY (2018-2029) & (US$ Million)
    Figure 38. Asia Malignant Mesothelioma Market Share by Type (2018-2029)
    Figure 39. Asia Malignant Mesothelioma Market Share by Application (2018-2029)
    Figure 40. Asia Malignant Mesothelioma Market Share by Region (2018-2029)
    Figure 41. Japan Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. South Korea Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. China Taiwan Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Southeast Asia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. India Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Australia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Malignant Mesothelioma Market Size YoY (2018-2029) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Malignant Mesothelioma Market Share by Type (2018-2029)
    Figure 49. Middle East, Africa, and Latin America Malignant Mesothelioma Market Share by Application (2018-2029)
    Figure 50. Middle East, Africa, and Latin America Malignant Mesothelioma Market Share by Country (2018-2029)
    Figure 51. Brazil Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 52. Mexico Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 53. Turkey Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 54. Saudi Arabia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 55. Israel Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 56. GCC Countries Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 57. AstraZeneca Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 59. Roche Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 60. Merck Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 61. Novartis Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 62. Pfizer Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 63. Sanofi Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 64. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 66. Boehringer Ingelheim GmbH Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 67. Mylan Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 68. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 69. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 70. Corden Pharma Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 71. Concordia International Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 72. Kyowa Hakko Kirin Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 73. Polaris Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 74. MolMed Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 75. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 76. Nichi-Iko Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)
    Figure 77. Bottom-up and Top-down Approaches for This Report
    Figure 78. Data Triangulation
    Figure 79. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Gene Therapy For Cancer Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-22G13317
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Cancer Biomarkers Detection Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-30Q5590
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Oncology Companion Diagnostic Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-14K8500
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Throat Cancer Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-8R8713
Fri Feb 23 00:00:00 UTC 2024

Add to Cart